[
  {
    "ts": null,
    "headline": "Rising as One, Shining as Many - Global New Material International opens a new chapter for Zhejiang entrepreneurs going global on 29 August 2025",
    "summary": "Hong Kong, China, Aug. 26, 2025 (GLOBE NEWSWIRE) -- As the global industrial chain undergoes reconstruction and China's manufacturing industry moves towards a \"breakthrough in quality\", Zhejiang entrepreneurs step onto the international stage once again. On August 29, 2025, a significant event for the globalization of China's materials industry will begin at Xizi Hotel in Hangzhou. Here, the Acquisition Closing Ceremony of Global New Material International's acquisition of Merck’s SUSONITY as we",
    "url": "https://finnhub.io/api/news?id=81c1c9e91da3cfbfd5b8bb6c953f512a19b67acf03315898089c5593a26a948f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756245600,
      "headline": "Rising as One, Shining as Many - Global New Material International opens a new chapter for Zhejiang entrepreneurs going global on 29 August 2025",
      "id": 136536477,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Hong Kong, China, Aug. 26, 2025 (GLOBE NEWSWIRE) -- As the global industrial chain undergoes reconstruction and China's manufacturing industry moves towards a \"breakthrough in quality\", Zhejiang entrepreneurs step onto the international stage once again. On August 29, 2025, a significant event for the globalization of China's materials industry will begin at Xizi Hotel in Hangzhou. Here, the Acquisition Closing Ceremony of Global New Material International's acquisition of Merck’s SUSONITY as we",
      "url": "https://finnhub.io/api/news?id=81c1c9e91da3cfbfd5b8bb6c953f512a19b67acf03315898089c5593a26a948f"
    }
  },
  {
    "ts": null,
    "headline": "Can Label Expansion of Cabometyx Fuel Further Growth for EXEL?",
    "summary": "The FDA approval to expand Exelixis' Cabometyx into neuroendocrine tumors is witnessing encouraging uptake and boosting investor focus.",
    "url": "https://finnhub.io/api/news?id=ca775025c48a3c64449643ed1591e9f9bf64a3798b3493a0212fdb4ef90531a3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756215060,
      "headline": "Can Label Expansion of Cabometyx Fuel Further Growth for EXEL?",
      "id": 136526723,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The FDA approval to expand Exelixis' Cabometyx into neuroendocrine tumors is witnessing encouraging uptake and boosting investor focus.",
      "url": "https://finnhub.io/api/news?id=ca775025c48a3c64449643ed1591e9f9bf64a3798b3493a0212fdb4ef90531a3"
    }
  },
  {
    "ts": null,
    "headline": "IOVA Stock Drops 6% on $350M Common Stock Offering",
    "summary": "Iovance shares slid 6% after unveiling a $350 million stock offering, raising dilution concerns while funding growth plans for Amtagvi and its pipeline.",
    "url": "https://finnhub.io/api/news?id=1cbad8cc4bbee27341cfe4e17968adc503d7457c732babe83619b3fa4bf4ebc9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756214220,
      "headline": "IOVA Stock Drops 6% on $350M Common Stock Offering",
      "id": 136525707,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Iovance shares slid 6% after unveiling a $350 million stock offering, raising dilution concerns while funding growth plans for Amtagvi and its pipeline.",
      "url": "https://finnhub.io/api/news?id=1cbad8cc4bbee27341cfe4e17968adc503d7457c732babe83619b3fa4bf4ebc9"
    }
  }
]